Baird Financial Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $772K | Sell |
4,213
-5,478
| -57% | -$1.01M | ﹤0.01% | 1339 |
|
|
2025
Q4 | $1.71M | Sell |
9,691
-3,057
| -24% | -$499K | ﹤0.01% | 1093 |
|
|
2025
Q3 | $1.79M | Buy |
12,748
+8,075
| +173% | +$1.09M | ﹤0.01% | 1090 |
|
|
2025
Q2 | $587K | Sell |
4,673
-5,010
| -52% | -$624K | ﹤0.01% | 1368 |
|
|
2025
Q1 | $1.33M | Buy |
9,683
+1,023
| +12% | +$146K | ﹤0.01% | 1089 |
|
|
2024
Q4 | $1.32M | Sell |
8,660
-20,782
| -71% | -$3.51M | ﹤0.01% | 1094 |
|
|
2024
Q3 | $5.71M | Buy |
29,442
+2,858
| +11% | +$598K | 0.01% | 637 |
|
|
2024
Q2 | $6.16M | Buy |
26,584
+5,381
| +25% | +$1.17M | 0.01% | 609 |
|
|
2024
Q1 | $4.57M | Sell |
21,203
-28,066
| -57% | -$6.57M | 0.01% | 686 |
|
|
2023
Q4 | $12.7M | Buy |
49,269
+317
| +0.6% | +$77.9K | 0.03% | 415 |
|
|
2023
Q3 | $12.6M | Sell |
48,952
-2,511
| -5% | -$672K | 0.03% | 383 |
|
|
2023
Q2 | $14.7M | Sell |
51,463
-1,457
| -3% | -$434K | 0.04% | 361 |
|
|
2023
Q1 | $14.7M | Sell |
52,920
-1,821
| -3% | -$504K | 0.04% | 356 |
|
|
2022
Q4 | $15.2M | Sell |
54,741
-12,784
| -19% | -$3.61M | 0.04% | 344 |
|
|
2022
Q3 | $18M | Sell |
67,525
-7,647
| -10% | -$1.62M | 0.05% | 305 |
|
|
2022
Q2 | $15.3M | Sell |
75,172
-14,550
| -16% | -$2.97M | 0.04% | 354 |
|
|
2022
Q1 | $18.9M | Buy |
89,722
+11,882
| +15% | +$2.58M | 0.05% | 320 |
|
|
2021
Q4 | $18.7M | Buy |
77,840
+3,823
| +5% | +$983K | 0.04% | 328 |
|
|
2021
Q3 | $20.9M | Buy |
74,017
+15,862
| +27% | +$5.2M | 0.05% | 297 |
|
|
2021
Q2 | $20.1M | Sell |
58,155
-14,821
| -20% | -$4.49M | 0.05% | 302 |
|
|
2021
Q1 | $20.4M | Sell |
72,976
-1,564
| -2% | -$422K | 0.06% | 293 |
|
|
2020
Q4 | $18.3M | Buy |
74,540
+13,159
| +21% | +$3.39M | 0.05% | 304 |
|
|
2020
Q3 | $17.4M | Buy |
61,381
+5,367
| +10% | +$1.5M | 0.06% | 287 |
|
|
2020
Q2 | $15M | Buy |
56,014
+25,679
| +85% | +$7.72M | 0.06% | 285 |
|
|
2020
Q1 | $9.6M | Sell |
30,335
-11,357
| -27% | -$3.45M | 0.04% | 329 |
|
|
2019
Q4 | $12.4M | Sell |
41,692
-18,706
| -31% | -$5.19M | 0.04% | 345 |
|
|
2019
Q3 | $14.1M | Sell |
60,398
-16,964
| -22% | -$3.95M | 0.06% | 298 |
|
|
2019
Q2 | $18.1M | Sell |
77,362
-3,998
| -5% | -$923K | 0.07% | 267 |
|
|
2019
Q1 | $19.2M | Sell |
81,360
-61,495
| -43% | -$19.4M | 0.11% | 219 |
|
|
2018
Q4 | $43M | Buy |
142,855
+658
| +0.5% | +$210K | 0.29% | 91 |
|
|
2018
Q3 | $50.1M | Sell |
142,197
-8,311
| -6% | -$2.86M | 0.31% | 85 |
|
|
2018
Q2 | $43.7M | Sell |
150,508
-1,788
| -1% | -$503K | 0.3% | 93 |
|
|
2018
Q1 | $41.7M | Buy |
152,296
+9,269
| +6% | +$2.88M | 0.29% | 97 |
|
|
2017
Q4 | $45.6M | Buy |
143,027
+3,954
| +3% | +$1.27M | 0.32% | 93 |
|
|
2017
Q3 | $43.5M | Buy |
139,073
+1,091
| +0.8% | +$323K | 0.33% | 89 |
|
|
2017
Q2 | $37.4M | Sell |
137,982
-1,189
| -0.9% | -$314K | 0.29% | 109 |
|
|
2017
Q1 | $38.1M | Buy |
139,171
+36,975
| +36% | +$10.5M | 0.31% | 94 |
|
|
2016
Q4 | $29M | Buy |
102,196
+7,172
| +8% | +$2.13M | 0.25% | 123 |
|
|
2016
Q3 | $29.7M | Buy |
95,024
+43
| +0% | +$12.7K | 0.27% | 106 |
|
|
2016
Q2 | $23.8M | Buy |
94,981
+22,894
| +32% | +$6.03M | 0.22% | 134 |
|
|
2016
Q1 | $18.8M | Buy |
72,087
+13,409
| +23% | +$3.54M | 0.18% | 160 |
|
|
2015
Q4 | $18M | Sell |
58,678
-3,615
| -6% | -$1.04M | 0.18% | 159 |
|
|
2015
Q3 | $18.2M | Buy |
62,293
+41,162
| +195% | +$13.6M | 0.19% | 147 |
|
|
2015
Q2 | $8.54M | Buy |
+21,131
| New | +$8.48M | 0.08% | 238 |
|
Other funds holding BIIB
VCM
VPM
Baird Financial Group's BIIB Position: Q1 2026 in Review
Baird Financial Group reduced its Biogen (BIIB) stake by 57% in Q1 2026, selling an estimated $1.01M and leaving 4,213 shares worth $772K. The position accounts for ﹤0.01% of the portfolio, ranked #1339.
Baird Financial Group first reported a position in BIIB in Q2 2015 and has held it in 44 quarters since. The position peaked at $50.1M in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Baird Financial Group held 4,213 shares of Biogen worth $772K as of Q1 2026.
- Baird Financial Group sold 5,478 Biogen shares in Q1 2026, an estimated $1.01M.
- Biogen made up ﹤0.01% of Baird Financial Group's portfolio in Q1 2026, its #1339 holding.
- Baird Financial Group first reported a position in Biogen in Q2 2015 and has held it in 44 quarters since.
- Baird Financial Group's Biogen position peaked at $50.1M in Q3 2018.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.